Your browser doesn't support javascript.
loading
CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism.
Cho, Hyelim; Shen, Qiong; Zhang, Lydia H; Okumura, Mikiko; Kawakami, Akinori; Ambrose, Jessi; Sigoillot, Frederic; Miller, Howard R; Gleim, Scott; Cobos-Correa, Amanda; Wang, Ying; Piechon, Philippe; Roma, Guglielmo; Eggimann, Fabian; Moore, Charles; Aspesi, Peter; Mapa, Felipa A; Burks, Heather; Ross, Nathan T; Krastel, Philipp; Hild, Marc; Maimone, Thomas J; Fisher, David E; Nomura, Daniel K; Tallarico, John A; Canham, Stephen M; Jenkins, Jeremy L; Forrester, William C.
Afiliación
  • Cho H; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Shen Q; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Zhang LH; Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
  • Okumura M; Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
  • Kawakami A; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Ambrose J; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Sigoillot F; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Miller HR; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Gleim S; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Cobos-Correa A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Wang Y; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Piechon P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Roma G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Eggimann F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Moore C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Aspesi P; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Mapa FA; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Burks H; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Ross NT; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Krastel P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
  • Hild M; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Maimone TJ; Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
  • Fisher DE; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Nomura DK; Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA; Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA; Department of Nutritional Sc
  • Tallarico JA; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
  • Canham SM; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
  • Jenkins JL; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jeremy.jenkins@novartis.com.
  • Forrester WC; Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: william.forrester@novartis.com.
Cell Chem Biol ; 28(10): 1407-1419.e6, 2021 10 21.
Article en En | MEDLINE | ID: mdl-33794192
ABSTRACT
Three limonoid natural products with selective anti-proliferative activity against BRAF(V600E) and NRAS(Q61K)-mutation-dependent melanoma cell lines were identified. Differential transcriptome analysis revealed dependency of compound activity on expression of the mitochondrial cytochrome P450 oxidase CYP27A1, a transcriptional target of melanogenesis-associated transcription factor (MITF). We determined that CYP27A1 activity is necessary for the generation of a reactive metabolite that proceeds to inhibit cellular proliferation. A genome-wide small interfering RNA screen in combination with chemical proteomics experiments revealed gene-drug functional epistasis, suggesting that these compounds target mitochondrial biogenesis and inhibit tumor bioenergetics through a covalent mechanism. Our work suggests a strategy for melanoma-specific targeting by exploiting the expression of MITF target gene CYP27A1 and inhibiting mitochondrial oxidative phosphorylation in BRAF mutant melanomas.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Limoninas / Colestanotriol 26-Monooxigenasa / Mitocondrias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Chem Biol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Limoninas / Colestanotriol 26-Monooxigenasa / Mitocondrias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cell Chem Biol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos